Next-generation viral vector platforms for gene therapy, vaccine, and oncolytic virotherapy applications

Viral vectors play a critical role in several pioneering biotherapeutic approaches, including gene therapy, immuno-oncology, and vaccines. However, their immunogenicity means that most vector-based in vivo gene therapies are currently unsuitable both for systemic delivery and repeat dosing. Synthetic vector platforms can help overcome these challenges.

Inanç Ortaç PhD, is the founder and CSO of DevaCell, a therapeutics company developing next generation cancer immunotherapies, gene therapies and vaccines; the founder and CSO of Sarmal, a genomics company working on a new generation of sequencing and target detection technologies; and the founder, and CSO of Innovasion Labs PINC that develops next generation energy storage devices including batteries and capacitors using a breakthrough bio-nanotechnology enabled self-assembly process.

After completing his BS in Physics at Middle East Technical University in Turkey, Inanc received a Fulbright Scholarship and moved to the US where he received MS and PhD degrees in Electrical and Computer Engineering at UC San Diego with specializations in biophotonics and nanotechnology.

Inanc has received several prestigious awards for his research and inventions including national Collegiate Inventors Competition Grand Prize in 2012 and recently Biocom’s Catalyst Award in 2020 among others. His activities lie at the interface of physics, chemistry, molecular biology, material science and optics.

Please enter your email to access content Read now